請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38362
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張上淳 | |
dc.contributor.author | Ying-Yu Chen | en |
dc.contributor.author | 陳盈宇 | zh_TW |
dc.date.accessioned | 2021-06-13T16:31:26Z | - |
dc.date.available | 2016-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-07-19 | |
dc.identifier.citation | 1.Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008; 29(11): 996-1011.
2.Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med. 2000; 342(10): 710-21. 3.Lai CC, Wang CY, Chu CC, Tan CK, Lu CL, Lee YL, et al. Correlation between antimicrobial consumption and resistance among Staphylococcus aureus and enterococci causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009. Eur J Clin Microbiol Infect Dis. 2011; 30(2): 265-71. 4.Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: A meta-analysis. Infect Control Hosp Epidemiol. 2003; 24(9): 690-8. 5.DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis. 2005; 41(3): 327-33. 6.Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect. 2010; 16(6): 555-62. 7.Mave V, Garcia-Diaz J, Islam T, Hasbun R. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? J Antimicrob Chemother. 2009; 64(1): 175-80. 8.Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med. 2001; 135(7): 484-92. 9.Han SH, Chin BS, Lee HS, Jeong SJ, Choi HK, Kim CO, et al. Vancomycin-resistant enterococci bacteremia: risk factors for mortality and influence of antimicrobial therapy on clinical outcome. J Infect. 2009; 58(3): 182-90. 10.Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs. 2002; 62(3): 425-41. 11.Arias CA, Murray BE. Enterococcus species, Streptococcus bovis group, and Leuconostoc species. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 7ed. Philadelphia, PA: Churchill Livingstone/Elsevier; 2010. p. 2643-53. 12.Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev. 2000; 13(4): 686-707. 13.Gordon S, Swenson JM, Hill BC, Pigott NE, Facklam RR, Cooksey RC, et al. Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group. J Clin Microbiol. 1992; 30(9): 2373-8. 14.Treitman AN, Yarnold PR, Warren J, Noskin GA. Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002). J Clin Microbiol. 2005; 43(1): 462-3. 15.Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA. Clin Infect Dis. 1999; 29(2): 259-63. 16.Mundy LM, Sahm DF, Gilmore M. Relationships between enterococcal virulence and antimicrobial resistance. Clin Microbiol Rev. 2000; 13(4): 513-22. 17.Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007; 58(2): 163-70. 18.Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet. 1988; 1(8575-8576): 57-8. 19.Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988; 319(3): 157-61. 20.Frieden TR, Munsiff SS, Low DE, Willey BM, Williams G, Faur Y, et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet. 1993; 342(8863): 76-9. 21.Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004; 39(3): 309-17. 22.Karlowsky JA, Jones ME, Draghi DC, Thornsberry C, Sahm DF, Volturo GA. Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. Ann Clin Microbiol Antimicrob. 2004; 3: 7. 23.Reynolds PE. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989; 8(11): 943-50. 24.Barna JC, Williams DH. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol. 1984; 38: 339-57. 25.Arthur M, Reynolds P, Courvalin P. Glycopeptide resistance in enterococci. Trends Microbiol. 1996; 4(10): 401-7. 26.Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis. 2006; 42 Suppl 1: S25-34. 27.Boyd DA, Willey BM, Fawcett D, Gillani N, Mulvey MR. Molecular characterization of Enterococcus faecalis N06-0364 with low-level vancomycin resistance harboring a novel D-Ala-D-Ser gene cluster, vanL. Antimicrob Agents Chemother. 2008; 52(7): 2667-72. 28.Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis. 1997; 24(4): 545-54; quiz 55-6. 29.Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993; 37(8): 1563-71. 30.Centers for Disease Control and Prevention (CDC). Nosocomial enterococci resistant to vancomycin--United States, 1989-1993. MMWR Morb Mortal Wkly Rep. 1993; 42(30): 597-9. 31.National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004; 32(8): 470-85. 32.Schouten MA, Hoogkamp-Korstanje JA, Meis JF, Voss A. Prevalence of vancomycin-resistant enterococci in Europe. Eur J Clin Microbiol Infect Dis. 2000; 19(11): 816-22. 33.Antimicrobial resistance surveillance in Europe 2009. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). [Database on the internet] [cited May 14, 2011]; Available from: http://www.ecdc.europa.eu/en/publications/Publications/1011_SUR_annual_EARS_Net_2009.pdf 34.Brown DF, Hope R, Livermore DM, Brick G, Broughton K, George RC, et al. Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother. 2008; 62 Suppl 2: ii75-85. 35.Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents. 2005; 26(1): 43-9. 36.Chiang PC, Wu TL, Su JY, Huang YC, Chiu YP, Chia JH, et al. Unusual increase of vancomycin-resistant Enterococcus faecium but not Enterococcus faecalis at a university hospital in Taiwan. Chang Gung Med J. 2007; 30(6): 493-503. 37.Shay DK, Maloney SA, Montecalvo M, Banerjee S, Wormser GP, Arduino MJ, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis. 1995; 172(4): 993-1000. 38.Lucas GM, Lechtzin N, Puryear DW, Yau LL, Flexner CW, Moore RD. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin Infect Dis. 1998; 26(5): 1127-33. 39.Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol. 1999; 20(5): 318-23. 40.Peset V, Tallon P, Sola C, Sanchez E, Sarrion A, Perez-Belles C, et al. Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur J Clin Microbiol Infect Dis. 2000; 19(10): 742-9. 41.Edmond MB, Ober JF, Weinbaum DL, Pfaller MA, Hwang T, Sanford MD, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis. 1995; 20(5): 1126-33. 42.Malathum K, Murray BE. Vancomycin-resistant enterococci: recent advances in genetics, epidemiology and therapeutic options. Drug Resist Updat. 1999; 2(4): 224-43. 43.Wang JL, Hsueh PR. Therapeutic options for infections due to vancomycin-resistant enterococci. Expert Opin Pharmacother. 2009; 10(5): 785-96. 44.Mekonen ET, Noskin GA, Hacek DM, Peterson LR. Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb Drug Resist. 1995; 1(3): 249-53. 45.Arias CA, Murray BE. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther. 2008; 6(5): 637-55. 46.Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis. 1998; 27(5): 1259-65. 47.Moreno F, Jorgensen JH, Weiner MH. An old antibiotic for a new multiple-resistant Enterococcus faecium? Diagn Microbiol Infect Dis. 1994; 20(1): 41-3. 48.Howe RA, Robson M, Oakhill A, Cornish JM, Millar MR. Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant enterococcus. J Antimicrob Chemother. 1997; 40(1): 144-5. 49.Montecalvo MA, Horowitz H, Wormser GP, Seiter K, Carbonaro CA. Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1995; 39(3): 794. 50.Taylor SE, Paterson DL, Yu VL. Treatment options for chronic prostatitis due to vancomycin-resistant Enterococcus faecium. Eur J Clin Microbiol Infect Dis. 1998; 17(11): 798-800. 51.Allerberger F, Klare I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother. 1999; 43(2): 211-7. 52.Akins RL, Haase KK. Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2005; 25(7): 1001-10. 53.Allington DR, Rivey MP. Quinupristin/dalfopristin: a therapeutic review. Clin Ther. 2001; 23(1): 24-44. 54.Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother. 1999; 44(2): 251-61. 55.Linden PK, Moellering RC, Jr., Wood CA, Rehm SJ, Flaherty J, Bompart F, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis. 2001; 33(11): 1816-23. 56.Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003; 36(2): 159-68. 57.Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA. 2001; 285(10): 1291. 58.Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003; 47(8): 2538-44. 59.Lakey JH, Ptak M. Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phospholipid membranes. Biochemistry (Mosc). 1988; 27(13): 4639-45. 60.Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy. 2009; 29(7): 792-9. 61.Kvirikadze N, Suseno M, Vescio T, Kaminer L, Singh K. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scand J Infect Dis. 2006; 38(4): 290-2. 62.Cha R, Grucz RG, Jr., Rybak MJ. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob Agents Chemother. 2003; 47(5): 1598-603. 63.Mohr JF, Friedrich LV, Yankelev S, Lamp KC. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). Int J Antimicrob Agents. 2009; 33(6): 543-8. 64.Oleson FB, Jr., Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 2000; 44(11): 2948-53. 65.Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother. 2006; 57(3): 578-9. 66.Papadopoulos S, Ball AM, Liewer SE, Martin CA, Winstead PS, Murphy BS. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis. 2006; 42(12): e108-10. 67.Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006; 26(8): 1099-110. 68.Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis. 2005; 52(3): 215-27. 69.Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother. 2005; 49(1): 220-9. 70.Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother. 2007; 59(1): 128-31. 71.Sader HS, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis. 2009; 65(2): 158-62. 72.Sader HS, Watters AA, Fritsche TR, Jones RN. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). BMC Infect Dis. 2007; 7: 29. 73.Raad I, Hachem R, Hanna H, Afif C, Escalante C, Kantarjian H, et al. Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother. 2004; 53(4): 646-9. 74.Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis. 2008; 46(1): 30-6. 75.Chong YP, Lee SO, Song EH, Lee EJ, Jang EY, Kim SH, et al. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance. Scand J Infect Dis. 2010; 42(6-7): 491-9. 76.Crank CW, Scheetz MH, Brielmaier B, Rose WE, Patel GP, Ritchie DJ, et al. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. Clin Ther. 2010; 32(10): 1713-9. 77.McKinnell JA, Patel M, Shirley RM, Kunz DF, Moser SA, Baddley JW. Observational study of the epidemiology and outcomes of vancomycin-resistant Enterococcus bacteraemia treated with newer antimicrobial agents. Epidemiol Infect. 2010: 1-9. 78.Jun JB, Choi SH, Lee SR, Jeon MH, Kwon HH, Lee SO, et al. Vancomycin-resistant enterococcal bacteremia in a hematology unit: risk factors for mortality and impact of adequate antimicrobial therapy on mortality. Infect Chemother. 2007; 39(3): 133-41. 79.Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med. 1998; 158(5): 522-7. 80.Garbutt JM, Ventrapragada M, Littenberg B, Mundy LM. Association between resistance to vancomycin and death in cases of Enterococcus faecium bacteremia. Clin Infect Dis. 2000; 30(3): 466-72. 81.Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000; 36(3): 145-58. 82.Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis. 2002; 34(7): 922-9. 83.Dubberke ER, Hollands JM, Georgantopoulos P, Augustin K, DiPersio JF, Mundy LM, et al. Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant. 2006; 38(12): 813-9. 84.Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5): 373-83. 85.American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992; 20(6): 864-74. 86.Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents. 1999; 11(1): 7-12. 87.Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13(10): 818-29. 88.Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002; 137(10): 791-7. 89.Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis. 2002; 35(10): 1139-46. 90.Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004; 8(4): R204-12. 91.Valles J, Calbo E, Anoro E, Fontanals D, Xercavins M, Espejo E, et al. Bloodstream infections in adults: importance of healthcare-associated infections. J Infect. 2008; 56(1): 27-34. 92.Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31(4): 1250-6. 93.Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis. 1997; 24(6): 1068-78. 94.Linden PK, Pasculle AW, Manez R, Kramer DJ, Fung JJ, Pinna AD, et al. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis. 1996; 22(4): 663-70. 95.Maki DG, Agger WA. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine (Baltimore). 1988; 67(4): 248-69. 96.Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008; 36(5): 309-32. 97.Chou YY, Lin TY, Lin JC, Wang NC, Peng MY, Chang FY. Vancomycin-resistant enterococcal bacteremia: comparison of clinical features and outcome between Enterococcus faecium and Enterococcus faecalis. J Microbiol Immunol Infect. 2008; 41(2): 124-9. 98.Ilavska I, Pichna P, Stopkova K, Grausova S, Krupova I, Oravcova E, et al. Polymicrobial bacteremia in cancer patients: analysis of risk factors, etiology and outcome in 214 episodes. Int J Antimicrob Agents. 1996; 7(2): 101-7. 99.Donskey CJ, Hanrahan JA, Hutton RA, Rice LB. Effect of parenteral antibiotic administration on persistence of vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract. J Infect Dis. 1999; 180(2): 384-90. 100.Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med. 2000; 343(26): 1925-32. 101.Noskin GA, Peterson LR, Warren JR. Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis. 1995; 20(2): 296-301. 102.Urdaneta M, Hollis F, Sperber S. Vancomycin-resistant enterococci in the blood (VREB): do we need to treat? Clin Infect Dis. 1995; 21(3): 730. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/38362 | - |
dc.description.abstract | 研究背景:
萬古黴素抗藥性Enterococcus faecium(vancomycin-resistant Enterococcus faecium,VREfm)菌血症之感染在近年來有上升的趨勢,而且臨床上能夠治療VREfm菌血症的藥物相當有限,因此在治療上格外地困難,然而目前對於VREfm菌血症之藥物治療結果以及病人預後相關之研究卻不多。 研究目的: 評估抗vancomycin-resistant enterococci(VRE)藥物之使用對於VREfm菌血症病人預後之影響,並進一步分析不同的抗生素對於VREfm菌血症之治療結果;另外也會分析VREfm菌血症發作後第30天之死亡危險因子。 研究設計、地點、對象: 本研究為單醫學中心之回溯性病歷分析,於國立臺灣大學醫學院附設醫院進行研究。研究對象為西元2009年1月1日至2010年12月31日感染VREfm菌血症之病人,只納入第一次感染事件,並排除年齡小於18歲及病歷資料不全者。 研究方法: 以紙本與電子病歷收集相關資料,包含病人基本資料、潛在疾病與造成菌血症感染之潛在因子、臨床表徵與相關檢驗數值、細菌培養結果、菌血症發作後之抗生素治療、後續追蹤與治療結果。本研究之主要觀察終點為菌血症發作後第30天之死亡率,並且利用單變項分析與多變項羅吉斯迴歸分析死亡危險因子以及抗生素治療對於病人預後之影響。 研究結果: 本研究共收入94位感染VREfm菌血症之成年病人,有93位(98.9%)病人為院內感染,有43位(45.7%)為單一菌種感染。全體病人之平均年齡為60.9±17.1歲,有57.4%為男性。在潛在疾病方面,以惡性腫瘤(62.8%)比例最高,其次為心血管疾病(55.3%)。在菌血症發作時,40.4%有敗血性休克,平均APACHE II score為 22.9±8.9。菌血症發作後第30天之死亡率在全體病人為55.3%,在單一菌種感染者則為48.8%。 在單一菌種感染方面,抗VRE藥物之使用對於其第30天之死亡率無顯著影響(P值0.67),而進一步分析不同抗生素之治療結果發現,linezolid組和daptomycin組在第30 天之死亡率也沒有達統計上顯著之差異(57.1% vs. 35.7%,P值0.26)。 在多變項羅吉斯迴歸分析中,全體病人於菌血症發作後第30天死亡之危險因子包含Charlson’s comorbidity index(勝算比1.47;95%信賴區間為1.12-1.93;P值0.006)、敗血性休克(勝算比3.13;95%信賴區間為1.08-9.05;P值0.0035)、APACHE II score≧23分(勝算比6.52;95%信賴區間為2.35-18.12;P值0.0003),而使用抗VRE藥物對於第30天之死亡率沒有影響(勝算比1.09;95%信賴區間為0.37-3.24;P值0.88);單一菌種感染者於菌血症發作後第30天死亡之危險因子只有APACHE II score≧23分(勝算比14.15;95%信賴區間為2.63-75.98;P值0.002),但是Charlson’s comorbidity index較高者有較高之趨勢會死亡,雖然未達統計上之顯著差異(勝算比1.53;95%信賴區間為0.96-2.44;P值0.07),而抗VRE藥物之使用對於第30天之死亡也沒有顯著之影響(勝算比1.19;95%信賴區間為0.21-6.92;P值0.84)。 結論: 從全體病人或是單一菌種感染者的多變項分析結果顯示,病人於VREfm菌血症發作時之合併症以及疾病嚴重程度才是影響病人於菌血症發作後第30天死亡之危險因子,而使用抗VRE藥物治療VREfm菌血症並無法改善病人之預後。 | zh_TW |
dc.description.abstract | Background:
Vancomycin-resistant Enterococcus faecium (VREfm) bacteremia has increased rapidly in recent years. Because few agents have activity against VREfm, it is difficult to treat VREfm bacteremia. However, there were limited studies that analyzed treatment outcomes and prognosis of VREfm bacteremia. Objectives: The present study was performed to evaluate the influence of anti-VRE therapy on prognosis of VREfm bacteremia patients and treatment outcomes of different antibiotic regimens. Risk factors for 30-day mortality were also assessed. Study design and study population: A retrospective chart review was conducted at National Taiwan University Hospital (NTUH), a medical center in northern Taiwan. Patients with bacteremia due to VREfm between January 1, 2009 and December 31, 2010 were enrolled. Only the first episode of bacteremia for each patient was included in the analysis. Patients younger than 18 years old or with incomplete medical records were excluded. Methods: Data were collected from medical records, including demographic data, underlying diseases, predisposing factors for infection, clinical presentation at the onset of VREfm bacteremia, laboratory data, microbiological data, antimicrobial treatment and outcomes. The primary end point was 30-day all-cause mortality. Univariate and multivariate stepwise logistic regression analyses were performed to determine risk factors for mortality and outcomes of antimicrobial treatment. Results: Ninety-four patients were enrolled in this study, and ninety-three (98.9%) were nosocomial infection. Among patients with VREfm bacteremia, forty-three (45.7%) patients were monomicrobial infection. The mean age was 60.9±17.1 years old and 57.4% were men. The most common underlying diseases were malignancy (62.8%), followed by cardiovascular diseases (55.3%). At the onset of bacteremia, 40.4% had septic shock and the mean APACHE II score was 22.9±8.9. The 30-day mortality was 55.3% for all patients and was 48.8% for patients with monomicrobial infection. Among patients with monomicrobial infection, receipt of anti-VRE therapy did not affect 30-day mortality (P=0.67). When further analyzing the treatment outcome between linezolid and daptomycin, there was no significant difference on 30-day mortality (57.1% vs. 35.7%,P=0.26). Multivariate logistic regression of patients with VREfm bacteremia showed that Charlson’s comorbidity index (odds ratio 1.47, 95%CI 1.12-1.93, P=0.006), septic shock (odds ratio 3.13, 95%CI 1.08-9.05, P=0.0035), APACHE II score≧23 (odds ratio 6.52, 95%CI 2.35-18.12, P=0.0003) were independent risk factors for 30-day mortality, but anti-VRE therapy was not associated with 30-day mortality (odds ratio 1.09, 95%CI 0.37-3.24, P=0.88). Among patients with monomicrobial infection, multivariate logistic regression revealed that only APACHE II score≧23 was associated with 30-day mortality (odds ratio 14.15, 95%CI 2.63-75.98, P=0.002), and higher Charlson’s comorbidity index showed a trend towards higher mortality (odds ratio 1.53, 95%CI 0.96-2.44, P=0.07). However, anti-VRE therapy was not a significant risk factor for 30-day mortality (odds ratio 1.19, 95%CI 0.21-6.92, P=0.84). Conclusions: This study showed that severity of illness and comorbidity at the onset of VREfm bacteremia had a significant influence on prognosis of patients, but receipt of anti-VRE therapy did not improve survival for patients. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T16:31:26Z (GMT). No. of bitstreams: 1 ntu-100-R98451004-1.pdf: 5729628 bytes, checksum: 35b724376972c54f5754431cf724276c (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 誌謝 i
中文摘要 ii Abstract v 目錄 viii 圖目錄 x 表目錄 xi 縮寫表 xiii 第一章 緒論 1 第二章 文獻探討 2 第一節 細菌學 2 第二節 流行病學 3 第三節 感染VREfm菌血症之危險因子 4 第四節 VREfm菌血症之治療藥物選擇 6 第五節 VREfm之體外藥物敏感性試驗 10 第六節 VREfm菌血症之藥物治療效果比較 11 第七節 VREfm菌血症之預後 15 第三章 研究目的 19 第四章 研究方法 20 第一節 研究設計 20 第二節 研究時間、地點與研究對象 21 第三節 資料收集 21 第四節 名詞定義 24 第五節 統計分析方法 26 第五章 研究結果 27 第一節 收案過程 27 第二節 病人基本資料 27 第三節 潛在疾病與感染菌血症之潛在因子 31 第四節 先前使用之抗生素 33 第五節 臨床表徵、疾病嚴重程度與感染來源 35 第六節 菌血症之治療與相關處置 37 第七節 死亡率 40 第八節 抗生素之使用、延遲抗生素治療與死亡率之關係 41 第九節 存活分析 46 第十節 VREfm菌血症之死亡危險因子 50 第六章 討論 61 第一節 感染VREfm菌血症之病人族群 61 第二節 死亡率之分析 62 第三節 VREfm菌血症之抗生素處方情形 63 第四節 Linezolid與daptomycin之治療結果比較 65 第五節 延遲抗生素治療 66 第六節 抗生素治療與死亡率之關係 66 第七節 VREfm菌血症之死亡危險因子分析 69 第八節 研究限制 71 第七章 結論 73 第八章 參考資料 74 附件一 個案報告表(Case Report Form) 85 附件二 APACHEII score 86 | |
dc.language.iso | zh-TW | |
dc.title | 萬古黴素抗藥性Enterococcus faecium菌血症:抗生素治療結果以及死亡危險因子分析 | zh_TW |
dc.title | Outcomes of Antimicrobial Treatment and Predictors of Mortality in Vancomycin-resistant Enterococcus faecium Bacteremia | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林慧玲,盛望徽,林淑文 | |
dc.subject.keyword | 抗生素治療,菌血症,Enterococcus faecium,死亡率,危險因子,萬古黴素抗藥性, | zh_TW |
dc.subject.keyword | Antimicrobial treatment,bacteremia,Enterococcus faecium,mortality,risk factors,vancomycin-resistant, | en |
dc.relation.page | 99 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-07-19 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 5.6 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。